Experience Matters
Providing expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia.
Welcome to Lucid Health Consulting
With over 30 years of Health Economics, Pricing & Reimbursement, Strategic Market Access and Health Technology Assessment experience, we have helped many organisations navigate the complexities of the Australian regulatory environment and achieve market access.
We have a proven track record of enabling companies and organisations to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.
Let us show you how our strategic approach and team experience can help you achieve market access in Australia.
How we can help your business?
What’s New
Read our articles, find out about our upcoming webinars and speaking engagements for the latest industry insights.
New Strategic Partnership with Vista Health in Asia Pacific Region
Lucid Health Consulting and Vista Health Forge Strategic Partnership across the Asia Pacific Region We are thrilled to announce a strategic partnership with Vista Health aimed at fortifying our joint commitment to delivering unparalleled health economics, HTA,...
HTAi 2023 Annual Meeting | LHC Poster and Presentation.
The HTAi Annual Meeting for 2023 was held this year in Adelaide on 24 – 28 June, with the theme: "The Road to Policy and Clinical Integration" The road to policy and clinical integration for health technologies is filled with diverse and complex challenges to...
ISPOR 2023 Boston, MA, USA, 7-10 May
Registration is now open for the ISPOR 2023 Conference, May 7 – 10 in Boston, MA, USA. This conference is the leading international conference for health economics and outcomes research (HEOR) and is a must-attend event providing dedicated opportunities to network...
What our clients are saying.
Lucid Health Consulting are providers of expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. Enabling companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.